Form 8-K - Current report:
SEC Accession No. 0001140361-24-048023
Filing Date
2024-11-29
Accepted
2024-11-29 06:02:14
Documents
14
Period of Report
2024-11-29
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20039354_8k.htm   iXBRL 8-K 36749
2 EXHIBIT 99.1 ef20039354_ex99-1.htm EX-99.1 19543
  Complete submission text file 0001140361-24-048023.txt   198665

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rvnc-20241129.xsd EX-101.SCH 3980
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvnc-20241129_lab.xml EX-101.LAB 21967
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvnc-20241129_pre.xml EX-101.PRE 16043
17 EXTRACTED XBRL INSTANCE DOCUMENT ef20039354_8k_htm.xml XML 4227
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

EIN.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 241513018
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)